Literature DB >> 22211956

Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms.

M İ Öztürk1, S Kalkan, O Koca, M Güneş, M Akyüz, M I Karaman.   

Abstract

Lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) are frequently encountered in ageing males. We compared the efficacy of alfuzosin 10 mg alone or in combination with sildenafil 50 mg in the treatment of LUTS due to benign prostatic hyperplasia. One hundred male patients older than 45 years were randomized to two groups containing 50 patients each; one group receiving alfuzosin 10 mg and the other group alfuzosin 10 mg combined with sildenafil 50 mg. International Prostate Symptom Score (IPSS), quality of life (QoL), maximum flow rate (Q(max)), prostate volume and post-void residual urine were evaluated. The mean age was 60.2 ± 17.8. Mean data of evaluated parameters in both groups at the end of 3rd month compared with baseline values are given respective order as; 5.1 (26.8%) and 5.8 (28.2%) points decreases in IPSS; 1.6 (41.1%) and 1.8 (45%) points decreases in QoL; and 3.4 (29.6%) and 3.4 (33%) points increases in Q(max) . The outcomes of our study cannot be interpreted in such a way to report that alpha blocker-PDE5 inhibitor combination has a better efficacy than alpha blocker treatment alone in patients with LUTS.
© 2011 Blackwell Verlag GmbH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22211956     DOI: 10.1111/j.1439-0272.2011.01268.x

Source DB:  PubMed          Journal:  Andrologia        ISSN: 0303-4569            Impact factor:   2.775


  8 in total

Review 1.  Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors.

Authors:  M Gacci; M Carini; M Salvi; A Sebastianelli; L Vignozzi; G Corona; M Maggi; K T McVary; S A Kaplan; M Oelke; S Serni
Journal:  Drugs Aging       Date:  2014-06       Impact factor: 3.923

Review 2.  Phosphodiesterase-5 expression and function in the lower urinary tract: a critical review.

Authors:  Ching-Shwun Lin; Maarten Albersen; Zhongcheng Xin; Mikio Namiki; Dieter Muller; Tom F Lue
Journal:  Urology       Date:  2013-01-17       Impact factor: 2.649

Review 3.  Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.

Authors:  Philipp Dahm; Michelle Brasure; Roderick MacDonald; Carin M Olson; Victoria A Nelson; Howard A Fink; Bruce Rwabasonga; Michael C Risk; Timothy J Wilt
Journal:  Eur Urol       Date:  2016-10-04       Impact factor: 20.096

Review 4.  Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH.

Authors:  Xing-Huan Wang; Xiao Wang; Ming-Jun Shi; Sheng Li; Tao Liu; Xin-Hua Zhang
Journal:  Asian J Androl       Date:  2015 Nov-Dec       Impact factor: 3.285

Review 5.  Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis.

Authors:  Andrea Mari; Alessandro Antonelli; Luca Cindolo; Ferdinando Fusco; Andrea Minervini; Cosimo De Nunzio
Journal:  Ther Adv Urol       Date:  2021-04-12

6.  The effect of pharmacotherapy on prostate volume, prostate perfusion and prostate-specific antigen (prostate morphometric parameters) in patients with lower urinary tract symptoms and benign prostatic obstruction. A systematic review and meta-analysis.

Authors:  Vasileios Sakalis; Anastasia Gkotsi; Dimitra Charpidou; Petros Tsafrakidis; Apostolos Apostolidis
Journal:  Cent European J Urol       Date:  2021-08-11

7.  Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis.

Authors:  Xinghuan Wang; Xiao Wang; Sheng Li; Zhe Meng; Tao Liu; Xinhua Zhang
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

8.  Efficacy and tolerability of combination therapy with alpha-blockers and phosphodiesterase-5 inhibitors compared with monotherapy for lower urinary tract symptoms: Protocol for a systematic review and network meta-analysis.

Authors:  Liu Qiangzhao; Zhang Xiaofeng; Zhou Fenghai; Lian Qiong; Zhang Fa; Guo Bohong; Xi Xinsheng
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.